Nuvalent (NUVL) Debt Ratio (2020)
Nuvalent (NUVL) reported Debt Ratio of 0.21 for Q4 2020.
Nuvalent (NUVL) Debt Ratio (2020) Analysis & Trends
Nuvalent has reported Debt Ratio for 1 years, with the latest figure at 0.21 in Q4 2020.
- For the quarter ending Q4 2020, Debt Ratio changed N/A year-over-year to 0.21; the trailing twelve-month figure through Dec 2020 stood at 0.21 (changed N/A YoY), and the FY2020 full-year result was 0.21, changed N/A from the prior year.
- Debt Ratio for Q4 2020 stood at 0.21.
- The five-year high for Debt Ratio was 0.21 in Q4 2020, with the low at 0.21 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 0.21 |